Interferon-Alfa-2A

Lymphoma

Hoffmann-La Rocheprotein_peptidePhase 3Dormant

B

59/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 56/ 100
Competitive Position: 65/ 100

Competitive context

288 Active assets in the Lymphoma cohort.

Asset / Sponsor	Phase	Rating
Vinblastine Intensity Therapeutics, Inc.	Phase 4	BBB
Prednisolone The Lymphoma Academic Research Organisation	Phase 4	BBB
Cyclophosphamide Beth Israel Deaconess Medical Center	Phase 4	BB
Vincristine Sulfate Inhye Ahn	Phase 3	BB
BLEOMYCIN Shandong Provincial Hospital	Phase 4	BB

View all 50 →

Same molecule, other indications

Interferon-Alfa-2A is also rated in:

renal cell carcinomaDormant

BB

Indicative · Phase 3

71 / 100

acute lymphoblastic leukemiaDormant

BB

Indicative · Phase 3

64 / 100

kidney cancerDormant

B

Indicative · Phase 3

62 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.